Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Novo Nordisk · Phase 2 · Completed · Enrollment 706

NCT03856047

EudraCT 2018-001945-14

ArmPopulationDoseWeeksEstimandWeight change
NNC0174-0833, 4.5 mgObesity or overweight4.5 mg26n/rn/r
NNC0174-0833, 2.4 mgObesity or overweight2.4 mg26n/rn/r
NNC0174-0833, 1.2 mgObesity or overweight1.2 mg26n/rn/r
NNC0174-0833, 0.6 mgObesity or overweight0.6 mg26n/rn/r
NNC0174-0833 0.3 mgObesity or overweight0.3 mg26n/rn/r
Placebo 2.4 mg (NNC0174-0833)Obesity or overweight2.4 mg26ITTn/r
Placebo 4.5 mg (NNC0174-0833)Obesity or overweight4.5 mg26ITTn/r
Placebo 1.2 mg (NNC0174-0833)Obesity or overweight1.2 mg26ITTn/r
Placebo 0.6 mg (NNC0174-0833)Obesity or overweight0.6 mg26ITTn/r
Placebo 0.3 mg (NNC0174-0833)Obesity or overweight0.3 mg26ITTn/r
Liraglutide 3.0 mgObesity or overweight3.0 mg26ITTn/r
Placebo 3.0 mg (Liraglutide)Obesity or overweight3.0 mg26ITTn/r